ChromaDex (CDXC) Announces Thorne Research Loses Patent Litigation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to ChromaDex (CDXC) Announces Thorne Research Loses Patent Litigation

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

August 15, 2022 6:34 AM EDT

The 807 patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) (the Company) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Offices Patent Trial and Appeal Boards (PTAB) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (the 807 patent). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from... More